PIONEERING THE NEXT GENERATION OF INGREDIENTS
Better Ingredients for Healthier Lives
DMC Biotechnologies is a U.S.-owned ingredient company developing high-purity, science-backed bioactives for health, wellness and personal care.
Powered by precision fermentation, our approach combines purity, consistency and traceability with scalable production—creating better ingredients for today and new possibilities for what comes next.
WHO WE ARE
Building the Next Generation of Health Ingredients
DMC Biotechnologies is bringing a new generation of health and wellness ingredients to market. Using precision fermentation, we produce high-purity, traceable and science-backed ingredients designed to support healthier lives.
Our first branded ingredient platform, KeyPura™, includes myo-inositol and D-chiro-inositol for a growing range of health and wellness applications. And we’re building beyond today’s portfolio—applying our capabilities to develop the bioactive ingredient solutions of tomorrow.
WHAT SETS DMC APART
From Science to Scalable Ingredients
Health-Focused Innovation
We start with meaningful health and wellness opportunities, developing ingredients around emerging science and evolving consumer needs.
Precision Fermentation
Our controlled production approach enables high purity, consistency and traceability while providing a scalable path to commercial supply.
Built for What’s Next
From today’s KeyPura™ portfolio to tomorrow’s bioactive ingredients, DMC is building a pipeline designed around real market opportunities and healthier lives.
Meet the Team
At DMC, our team is the driving force behind our mission to revolutionize chemical production through sustainable innovation. Comprised of industry experts, visionary scientists, and dedicated professionals, we are committed to advancing precision fermentation and synthetic biology.
Management Team
Our management team has broad experience in fermentation, renewable chemicals, and process industries.
Jim Flatt, PhD
Chief Executive Officer
Jim Flatt, Ph.D.
Chief Executive Officer
Dr. Jim Flatt brings over three decades of leadership in the biotechnology and renewable products industries to DMC Biotechnologies. With a Ph.D. in Chemical Engineering from the University of Wisconsin and advanced degrees from UC Berkeley and MIT, Jim has a proven track record of innovation in bioactives, precision fermentation, and sustainable solutions.
He co-founded Brightseed, where he pioneered AI-driven health ingredient discovery and led the company to commercial success, securing over $125M in funding. His leadership spans roles at Synthetic Genomics, Martek Biosciences, and Monsanto, where he successfully scaled and commercialized novel technologies. Jim’s expertise in biotechnology, product development, and strategic growth positions him to lead DMC into its next phase of impactful innovation.
ERNESTO SIMON
Chief Technology Officer
ERNESTO SIMON
Chief Technology Officer
Ernesto Simon has 20 years of experience in metabolic engineering and industrial biotech and has led the development of various precision fermentation-based products from bench to commercial scale. He has worked with a diverse range of synthetic biology companies including Evolva (now Lallemand), Firmenich (now dsm-firmenich), Conagen, and Cemvita.
SVP, Business Development
RUSTY PITTMAN
SVP, BD
Rusty Pittman has over 25 years of commercial experience in the chemical, building materials, and renewable energy industries. Rusty was previously with Elevance Renewable Sciences, Inc where he spent the last six years as VP/Head of Marketing and Business Development.
VP, Strategic Alliances
MARCEL LUBBEN, Ph.D.
VP, Strategic Alliances
Successful clean chemistry executive with accomplishments across multiple technologies and markets.
Robert Grysen
VP Operations and Quality
Robert Grysen
VP, Operations and Quality
With more than 15 years of experience in biotechnology, food ingredients, and manufacturing, Rob has built and led cross-functional organizations spanning operations, quality, supply chain, regulatory affairs, product development, and commercial execution. His expertise lies in transforming innovative technologies into scalable, market-ready products while establishing the systems and processes needed for reliable manufacturing and long-term growth.
Rhod Jenkins
VP of Process R&D and Scale-Up
Rhod Jenkins
VP of Process R&D and Scale-Up
Rhod Jenkins has over a decade of experience in biotechnology, bioprocessing, and chemical process development, with a focus on scale-up and commercialization of fermentation-derived products. He has led multidisciplinary teams to move processes from the laboratory through to commercial production, with expertise spanning bioprocessing, downstream purification, analytical characterization, technology transfer, and external manufacturing management. Prior to joining DMC, Rhod held technical leadership and R&D roles at Debut Biotechnology, Demetrix, Amyris, and Los Alamos National Laboratory.
Asa Goldenberg
Director, Business Operations
Asa Goldenberg
Director, Business Operations
Asa has over 25 years of business management experience, including 22 years in the healthcare sector. She plays a key role in supporting the leadership team and overseeing operations at DMC’s North Carolina branch. Asa’s broad expertise spans critical business functions such as operational scheduling, business communications, financial management, procurement, human resources, staff development, conflict resolution, policy creation, and event planning. Her comprehensive skill set enables her to navigate complex challenges and contribute significantly to the smooth functioning and strategic direction of DMC.
Lab and Facility Manager
Cathy St Louis
Lab and Facility Manager
Cathy has over 10 years of experience as a Lab and Safety Manager. Prior to working at DMC, she worked for a large University managing over 40 instructional labs, 20 lab assistants, and 4 assistant lab managers. She then transitioned to the field of EH&S (Environmental, Health and Safety) where she managed chemical and radioactive waste streams.
Founding Team
Our founding team are serial entrepreneurs and leaders in synthetic biology and fermentation.
MATT LIPSCOMB, PH.D.
Matt Lipscomb, Ph.D.
Founder
Dr. Lipscomb is a Founder of DMC, Inc. and served as CEO from 2014 to 2023. He now serves on the Board of Directors. His career has included a range of development stages from early R&D to commercial deployment in a variety of sectors, including both industrial and pharmaceutical biotechnology. Previously, he was a founding employee of OPX Biotechnologies and served in various roles during his tenure there. His technical leadership supported multiple successful fundraising rounds totaling more than $60M. He provided project leadership on the execution of a successful Department of Energy (DOE) ARPA-E Electrofuels program ($6M) for the production of biodiesel from H2 and CO2. His technical expertise includes microbial fermentation, process development, process modeling, analytical chemistry, and techno economic analysis (TEA) of bio-based processes.
MIKE LYNCH MD, Ph.D.
Founder
Dr. Lynch is a Founder of DMC, Inc. He is also an Assistant Professor in the Biomedical Engineering and Chemistry Departments at Duke University. Previously, Mike was founder and CSO of OPX Biotechnologies, Inc. where he led development efforts resulting in the successful piloting and demonstration of technology for the production of 3-hydroxy propionic acid (a precursor to the large volume commodity chemical, acrylic acid) and fatty acids from sugars via fermentation utilizing engineered biocatalysts. At Duke, Dr. Lynch and his team have recently developed the Synthetic Metabolic Valve technology enabling dynamic metabolic control of microbial metabolism in the context of a standardized bioprocess.
Directors & Investors
Our directors and investors are global leaders within the synthetic biology, chemicals, and ESG industries.
K’LYNNE JOHNSON
Chair of the Board
K’LYNNE JOHNSON
CHAIR OF THE BOARD
An entrepreneurial leader leveraging over 25 years of experience successfully bridging the capability to both build new innovative new technology businesses and transform existing large multi-billion traditional commodity organizations. Demonstrated broad experience base includes identifying and commercializing transformational technology and implementing growth strategies for existing businesses.
K’Lynne was the founding CEO of Elevance Renewable Sciences, a leading specialty chemicals company utilizing renewable feedstocks, and has a broad background of global operational management in both P&L and functional leadership roles within Innovene, BP and Amoco Corporation.
Jim Flatt, PhD
Director
Jim Flatt, Ph.D.
Director
Dr. Jim Flatt brings over three decades of leadership in the biotechnology and renewable products industries to DMC Biotechnologies. With a Ph.D. in Chemical Engineering from the University of Wisconsin and advanced degrees from UC Berkeley and MIT, Jim has a proven track record of innovation in bioactives, precision fermentation, and sustainable solutions.
He co-founded Brightseed, where he pioneered AI-driven health ingredient discovery and led the company to commercial success, securing over $125M in funding. His leadership spans roles at Synthetic Genomics, Martek Biosciences, and Monsanto, where he successfully scaled and commercialized novel technologies. Jim’s expertise in biotechnology, product development, and strategic growth positions him to lead DMC into its next phase of impactful innovation.
ANDRAS FORGACS
Director
Andras Forgacs is an entrepreneur and investor in deep tech and life sciences, and Founder and Managing Partner of Inceptional Partners, which backs critical technologies at critical inflection points. Previously Managing Partner at Starlight Ventures, he has backed more than 40 companies. He was founding CEO of Modern Meadow and co-founded Fork & Good and Organovo (NASDAQ). He chairs the board of Geltor, teaches venture capital at the University of Miami Herbert Business School, and serves as chair of YPO Miami Gateway. He is a Kauffman Fellow and holds degrees from Harvard and Wharton.
DOUG CAMERON
INDEPENDENT DIRECTOR
Doug brings more than 30 years of experience in the biotech industry and has deep knowledge of technology, commercialization, venture capital, and private equity. He earned a Ph.D. in Biochemical Engineering from MIT and has worked for Cargill, Khosla Ventures, and First Green Partners, among others.
JOŠKO BOBANOVIĆ
Observer
Joško Bobanović joined Sofinnova in 2010 as a partner focused on the industrial biotech strategy. He works on early stage deals in Europe and North America with applications in chemicals, agriculture, food, and materials. Prior to joining Sofinnova Partners, he was part of the investment team at iNovia Capital in Montreal, Canada. In addition to DMC’ board, Joško sits on the boards of Metgen, Comet Bio, DNA Script, Biosyntia, Pyrowave and Protera Biosciences. Before going into venture capital, he created an internet startup and a software company. He is a mentor at BIRD Incubator, which helps entrepreneurs in software, data analytics, artificial intelligence, and machine learning.
ROB VAN DER MEIJ
Observer
Rob is a chemical engineer from Delft University in the Netherlands and has worked both in the corporate, strategy consulting and start-up world in chemicals, process and water technology. Rob has held business management positions with Akzo Nobel and Shell Chemicals, was a founder and CEO of KiOR in the US and worked as CEO for several other start-ups in chemicals and water technology. He is also an investor and has board roles in several start-ups.
ALASTAIR COOPER
Observer
Alastair Cooper is a Senior Investment Director at ADM Capital with responsibility for Early Stage Investments. Alastair spent 18 years as an Investment Banker, 16 years of which were at Morgan Stanley, within the Equity Division, as a Managing Director based in London and Hong Kong. His responsibilities included Head of European Derivatives, Proprietary Trading and Head of Asian Equity. Upon leaving Morgan Stanley in 2002, Alastair completed the One Year Farming Course at the Royal Agricultural College and has managed his own mixed organic farm since. As an active private investor, Alastair has made a number of investments within renewable energy and agriculture. Alastair holds a BSc in Zoology from Exeter University, England.
Veronica Breckenridge
Observer
VERONICA BRECKENRIDGE
Observer
Veronica Breckenridge is the Founder and Managing Partner of First Bight Ventures, a Houston-based venture firm backing early-stage industrial biomanufacturing startups ready to scale production and commercialize. A seasoned global executive, Veronica previously served as VP at Tesla, where she launched the company’s China operations, and General Manager at Apple, overseeing non-consumer business in Greater China. Her background also includes leadership roles at Motorola and McKinsey & Company. As founding partner of the CSC Upshot Fund, she managed a portfolio recognized by Stanford Business School as a top Unicorn investor. Veronica studied Applied Mathematics at Yale and pursued graduate studies in Operations Research at UC Berkeley.
Our Locations
JOIN THE TEAM
AT DMC
Become part of a dynamic team driving innovation and sustainability in biotechnology.